Thomas Powles outlines the primary results of the phase 3 EV-301 trial comparing enfortumab vedotin with chemotherapy in patients who have received prior treatment for locally advanced or metastatic urothelial carcinoma (4:37).
This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany.